ArticleBreast cancer (Tokyo, Japan)2024

Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR-/HER2+ breast cancer subtypes.

Wu Ding et al.PubMed ↗Publisher ↗

No numbers read from the abstract.